Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof
AssigneesNuclidium AG, University of Basel
InventorsLeila Jaafar-Thiel, Francesco De Rose, Melpomeni Fani, Jacopo Millul
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions comprising a [61Cu]Cu-labeled fibroblast activation protein (FAP) inhibitor-NODAGA conjugate. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a FAP-expressing cancer or tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.
Claims31
A method for imaging a subject comprising:
- (a) administering an effective amount of a pharmaceutical composition to a subject suspected of having or diagnosed with a disorder associated with expression of fibroblast activation protein (FAP), wherein the pharmaceutical composition comprises:
- i. a radiotracer that has one of the following structures
- Radiotracer
- Structure
- 61Cu-NODAGA-1
- 61Cu-NODAGA-2
- 61Cu-NODAGA-3
- 61Cu-NODAGA-4
- or is a pharmaceutically acceptable salt thereof;
- and
- ii. a radiolytic inhibitor;
- wherein the pharmaceutical composition is characterized by one or more of:
- a [61Cu]Cu radionuclidic purity at end of synthesis of ≥97%,
- a radiocobalt activity content at end of synthesis of ≤0.05%,
- a 110mAg specific activity ≤0.1 Bq/g,
- a 108mAg specific activity ≤0.1 Bq/g, or
- a 109Cd specific activity ≤0.1 Bq/g;
- and
- (b) generating one or more radiographic images of the subject.
(canceled)
A method for determining a subject's response to a cancer treatment comprising:
- (a) administering an effective amount of a pharmaceutical composition to a subject diagnosed with a fibroblast activation protein (FAP)-expressing cancer or tumor at an earlier time point and at a later time point, wherein the pharmaceutical composition comprises:
- i. a radiotracer that has one of the following structures
- Radiotracer
- Structure
- 61Cu-NODAGA-1
- 61Cu-NODAGA-2
- 61Cu-NODAGA-3
- 61Cu-NODAGA-4
- or is a pharmaceutically acceptable salt thereof;
- and
- ii. a radiolytic inhibitor;
- wherein the pharmaceutical composition is characterized by one or more of:
- a [61Cu]Cu radionuclidic purity at end of synthesis of ≥97%,
- a radiocobalt activity content at end of synthesis of ≤0.05%,
- a 110mAg specific activity ≤0.1 Bq/g,
- a 108mAg specific activity ≤0.1 Bq/g, or
- a 109Cd specific activity ≤0.1 Bq/g;
- (b) generating one or more radiographic images of the subject at the earlier time point and at the later time point;
- (c) determining the amount of localization of the radionuclide in the one or more radiographic images of the subject at the earlier time point and at the later time point;
- and
- (d) determining the subject's response to the cancer treatment by comparing the amount of localization of the radionuclide in the one or more radiographic images of the subject at the earlier time point and at the later time point.
4-54. (canceled)
A pharmaceutical composition comprising:
- (a) a radiotracer that has one of the following structures
- Radiotracer
- Structure
- 61Cu-NODAGA-1
- 61Cu-NODAGA-2
- 61Cu-NODAGA-3
- 61Cu-NODAGA-4
- or is a pharmaceutically acceptable salt thereof,
- (b) a radiolytic inhibitor, and
- (c) an aqueous vehicle;
- wherein the pharmaceutical composition is characterized by one or more of:
- a [61Cu]Cu radionuclidic purity at end of synthesis of ≥97%,
- a radiocobalt activity content at end of synthesis of ≤0.05%,
- a 110mAg specific activity ≤0.1 Bq/g,
- a 108mAg specific activity ≤0.1 Bq/g, or
- a 109Cd specific activity ≤0.1 Bq/g.
(canceled)
(canceled)
63-65. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.